Plexus Corp.'s SEC filings document operating results, financial condition, governance matters and material corporate events for its complex product design, manufacturing and services business. Recent 8-K reports furnish quarterly and fiscal-year earnings releases and related financial information for the company's product lifecycle operations across regulated end markets.
The filings also record shareholder meeting results, including director elections, advisory executive compensation votes and auditor ratification, as well as officer transition and compensation-arrangement disclosures. These records describe formal governance actions, executive roles and recurring public-company reporting obligations for PLXS.
Plexus Corp. executive Patrick J. Jermain, Exec. VP & CFO, reported multiple equity transactions in Plexus Corp. (PLXS). On 02/12/2026, he completed an open-market sale of 2,321 shares of common stock at $201.1229 per share, leaving 14,561 directly held shares afterward.
On 02/17/2026, 5,611 Performance Stock Units were exercised/converted into common stock, increasing his direct holdings to 20,172 shares. In a separate tax-related move that same day, 2,638 shares were disposed of at $195.95 to cover tax obligations, resulting in 17,534 directly held shares.
The filing also shows 3,751 shares of common stock held indirectly in the Plexus Corp. 401(k) Retirement Plan. A footnote explains that, based on company performance over a three-year period, 142.4% of the portion of fiscal 2023 Performance Stock Units tied to relative total shareholder return vested, versus a maximum opportunity of up to 150%.
Plexus Corp regional president Frank Zycinski sold his remaining common shares in an open-market trade. On 02/12/2026 he sold 1,399 shares of Plexus common stock at a weighted average price of $205.9925 per share, leaving him with 0 shares beneficially owned directly.
The sales were executed in multiple trades at prices ranging from $205.96 to $205.995 per share, with the reported figure reflecting the weighted average sale price.
Plexus Corp. has a new significant institutional holder. A regulatory disclosure shows that American Century Investment Management, American Century Companies, and the Stowers Institute for Medical Research together beneficially own 1,560,622 shares of Plexus common stock, representing 5.8% of the outstanding class as of December 31, 2025.
The group reports sole voting power over 1,426,523 shares and sole dispositive power over 1,560,622 shares. They state that the shares were acquired and are held in the ordinary course of business, not to change or influence control of Plexus.
Plexus Corp. insider plans additional stock sale under Rule 144. A holder intends to sell 2,321 shares of Plexus common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $466,806.25 and 26,786,466 shares outstanding as of the notice.
The shares to be sold were acquired as performance shares from the issuer on 02/11/2025. The filing also lists prior sales by Patrick Jermain over the past three months, including 3,587 and 4,841 common shares sold on 02/04/2026 and 02/03/2026, respectively, with gross proceeds of $732,070.83 and $987,612.41.
A shareholder of PLXS filed a Rule 144 notice to sell 1,399 shares of common stock through Morgan Stanley Smith Barney LLC on 02/12/2026 on the NASDAQ, with an aggregate market value of $288,183.51 and 26,786,466 shares outstanding.
The shares to be sold were acquired as restricted stock from the issuer, including 676 shares acquired on 01/30/2026 and additional blocks of 165 and 558 shares acquired on 01/31/2025, all listed as fully paid in cash-equivalent terms.
Wuamett Jennifer reported acquisition or exercise transactions in this Form 4 filing.
Plexus Corp. director Jennifer Wuamett received a grant of 1,008 restricted stock units on February 9, 2026. Each unit represents a contingent right to one share of Plexus common stock and was issued under the Plexus Corp. 2024 Omnibus Incentive Plan.
The restricted stock units vest on February 9, 2027, meaning the director receives the underlying shares if vesting conditions are satisfied. After this award, she directly holds 1,008 restricted stock units and 3,349 shares of Plexus common stock.
SCHROCK MICHAEL V reported acquisition or exercise transactions in this Form 4 filing.
Plexus Corp director Michael V. Schrock received a grant of 1,008 Restricted Stock Units (RSUs) on February 9, 2026 under the Plexus Corp 2024 Omnibus Incentive Plan. Each RSU represents a right to one share of common stock and will vest on February 9, 2027.
Following this award, Schrock directly holds 44,329 shares of Plexus common stock and 1,008 RSUs, giving him both current ownership and a contingent future interest tied to the company’s equity.
ROOKE PAUL A reported acquisition or exercise transactions in this Form 4 filing.
Plexus Corp director Paul A. Rooke received a grant of 1,008 Restricted Stock Units on February 9, 2026 under the Plexus Corp. 2024 Omnibus Incentive Plan. Each unit represents a contingent right to receive one share of Plexus common stock and will vest on February 9, 2027.
After this award, Rooke directly beneficially owned 15,991 shares of Plexus Corp common stock, according to the filing.
Rapp Karen Marie reported acquisition or exercise transactions in this Form 4 filing.
Plexus Corp director Karen Rapp reported an equity award on Form 4. On February 9, 2026, she received a grant of 1,008 restricted stock units under the Plexus Corp 2024 Omnibus Incentive Plan. Each unit represents a contingent right to one share of Plexus common stock and vests on February 9, 2027.
Following this award, she directly owned 1,008 restricted stock units and 9,035 shares of Plexus Corp common stock, as reported in the filing.
Quadracci J Joel reported acquisition or exercise transactions in this Form 4 filing.
Plexus Corp director J. Joel Quadracci received a grant of 1,008 restricted stock units on February 9, 2026 under the Plexus Corp 2024 Omnibus Incentive Plan. Each unit represents a contingent right to one share of Plexus common stock and vests on February 9, 2027.
After this grant, Quadracci directly beneficially owns 7,478 shares of Plexus Corp common stock, plus the 1,008 restricted stock units reported in the derivative securities table.